Allison Elaine Burns, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 1 Choctaw Way, Talihina, OK 74571 Phone: 918-567-7000 |
Rhonda Ruth Huie, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 1 Choctaw Way, Talihina, OK 74571 Phone: 918-567-7000 Fax: 918-567-7038 |
Kayla Price, Physician Assistant - Medical Medicare: Accepting Medicare Assignments Practice Location: 1 Choctaw Way, Talihina, OK 74571 Phone: 918-567-7000 Fax: 918-567-7113 |
Hannah Rae Huddleston, Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 1 Choctaw Way, Talihina, OK 74571 Phone: 918-567-7000 |
Olin Nicholas Perkins, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 1 Choctaw Way, Talihina, OK 74571 Phone: 918-567-3065 |
Mr. Herve Arthur Lucier, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 1 Choctaw Way, Talihina, OK 74571 Phone: 918-567-7000 Fax: 918-567-7092 |
Mrs. Mary Ann Boerner, PA-C Physician Assistant - Medical Medicare: Accepting Medicare Assignments Practice Location: 1 Choctaw Way, Talihina, OK 74571 Phone: 918-567-7000 Fax: 918-567-7044 |
Mr. Thomas B. Hagelberger, PA Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: One Choctaw Way, Choctaw Nation Health Care Center, Talihina, OK 74571 Phone: 918-567-7000 |
Mr. Dean Newton Anderson, P.A.-C Physician Assistant - Medical Medicare: Accepting Medicare Assignments Practice Location: 1 Choctaw Way, Talihina, OK 74571 Phone: 918-649-1100 Fax: 918-649-1199 |
News Archive
Three-quarters of all breast cancer tumors are driven by the hormone estrogen. These tumors are frequently treated with drugs to suppress estrogen receptor activity, but unfortunately, at least half of patients do not respond to these treatments, leaving them with drug-resistant tumors and few options.
An international study led by Melbourne researchers has discovered nine new genes linked to the most severe type of childhood speech disorder, apraxia.
The doses of estrogen and progestogen used in menopausal hormone therapy may be related to the risk of breast cancer recurrence, according to a new study in the April 6 issue of the Journal of the National Cancer Institute.
Boehringer Ingelheim Pharmaceuticals, Inc. today reported preliminary results from the randomized Phase II part of a Phase I/II study involving the company's investigational compound volasertib in newly diagnosed patients with acute myeloid leukemia (AML) considered ineligible for intensive remission induction therapy.
› Verified 5 days ago